Sarah Teixeira, APRN
Payments from drug & device makers
Across 235 payments — averaging $22.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$946
- AstraZeneca$911
- Boehringer Ingelheim$447
- Jazz Pharmaceuticals Inc.$418
- Regeneron Healthcare Solutions, Inc.$281
- Advanced Respiratory, Inc$232
- plus $2K from 32 others
What the payments were for
- Food & beverage$5,09996%
- Education$2094%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 56 | $946 |
| AstraZeneca | 23 | $911 |
| Boehringer Ingelheim | 29 | $447 |
| Jazz Pharmaceuticals Inc. | 9 | $418 |
| Regeneron Healthcare Solutions, Inc. | 14 | $281 |
| Advanced Respiratory, Inc | 22 | $232 |
| Baxter Healthcare | 11 | $174 |
| Lilly USA, LLC | 2 | $140 |
| Teva Pharmaceuticals USA, Inc. | 1 | $138 |
| Mallinckrodt Hospital Products Inc. | 5 | $123 |
| Johnson & Johnson | 6 | $119 |
| Inspire Medical Systems, Inc. | 5 | $116 |
| Boston Scientific | 4 | $108 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 4 | $103 |
| Harmony Biosciences LLC | 4 | $97 |
| AbbVie | 1 | $93 |
| Scpharmaceuticals Inc. | 3 | $90 |
| Tactile Systems Technology Inc | 1 | $83 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $64 |
| Mylan Specialty L.p. | 3 | $61 |
| CSL Behring | 2 | $53 |
| Novartis | 3 | $53 |
| Lexicon Pharmaceuticals, Inc. | 3 | $53 |
| Bayer | 3 | $51 |
| Actelion Pharmaceuticals US, Inc. | 2 | $43 |
| Sanofi | 2 | $42 |
| Idorsia Pharmaceuticals US Inc | 2 | $37 |
| Pfizer | 2 | $36 |
| Insmed, Inc. | 1 | $26 |
| Merck | 1 | $24 |
| Chiesi USA, Inc. | 1 | $23 |
| Resmed Corp | 1 | $21 |
| Amgen | 1 | $19 |
| Breas Medical, Inc. | 1 | $19 |
| Electromed, Inc. | 1 | $18 |
| Novo Nordisk | 1 | $16 |
| Ferring Pharmaceuticals Inc. | 1 | $16 |
| Cardiva Medical, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BREZTRI$331
- TRELEGY ELLIPTA$218
- Austedo XR$138
- ZEPBOUND$121
- XYWAV$110
- FASENRA$104
How this compares
$5,308 in reported general payments places this provider in the 90th percentile of 1,501 family providers in Nevada.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 71 | $77,347 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 20 | $18,625 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 27 | $15,032 |
| Breo ElliptaFluticasone/Vilanterol | 21 | $10,347 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 13 | $7,043 |
| Arnuity ElliptaFluticasone Furoate | 18 | $5,243 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 54 | $1,353 |
| Pregabalin | 12 | $445 |
| Fluticasone Propionate | 13 | $188 |
| Montelukast Sodium | 11 | $82 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Arnuity Ellipta | $946 | $107,969137 claims |
| AstraZenecaBreztri Aerosphere | $911 | $18,62520 claims |
| Boehringer IngelheimStiolto Respimat | $447 | $7,04313 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,501 family providers in Nevada.
Other family in Reno
- Lisa Hammargren-KuykendallReno$22K
- Martha AiyukReno$15K
- Jocelyn AllenReno$12K
- Kaylie HumphreysReno$11K
- Christina KrainbrinkReno$10K
- Barbara SzatkowskiReno$10K
- Johanna LeeReno$9K
- Darin OldeReno$9K
- Ruth SkinnerReno$8K
- Anna EllisReno$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.